Patents by Inventor Wayne D. Inman

Wayne D. Inman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6552085
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: April 22, 2003
    Assignee: Insmed Incorporated
    Inventors: Wayne D. Inman, David C. Hopp
  • Patent number: 6541522
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as a dietary supplement to mammals suffering from elevated triglyceride levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypotriglyceridemic agents.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: April 1, 2003
    Assignee: Insmed Incorporated
    Inventors: Wayne D. Inman, David C. Hopp
  • Patent number: 6410596
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: June 25, 2002
    Assignee: Insmed Incorporated
    Inventors: David C. Hopp, Wayne D. Inman
  • Publication number: 20020058701
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 16, 2002
    Inventors: Wayne D. Inman, David C. Hopp
  • Publication number: 20020058707
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 16, 2002
    Inventors: David C. Hopp, Wayne D. Inman
  • Publication number: 20020058708
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as a dietary supplement to mammals suffering from elevated triglyceride levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypotriglyceridemic agents.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 16, 2002
    Inventors: Wayne D. Inman, David C. Hopp
  • Publication number: 20020055541
    Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as a dietary supplement to mammals suffering from elevated triglyceride levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypotriglyceridemic agents.
    Type: Application
    Filed: August 2, 2001
    Publication date: May 9, 2002
    Applicant: Shaman Pharmaceuticals, Inc.
    Inventors: Wayne D. Inman, David C. Hopp
  • Patent number: 5747527
    Abstract: Novel hypoglycemically active eremophilanolide sesquiterpenes which can be isolated from Psacalium spp., processes for obtaining the novel eremophilanolide sesquiterpenes and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. Further described is the use of epicacalone, cacalone, cacalol or dimaturin as hypoglycemic agents, for example, in the treatment of diabetes. In a preferred embodiment, the hypoglycemically active compounds are obtained from the roots of Psacalium decompositum. As agents for the treatment of diabetes, the hypoglycemically active compounds of the present inventions are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 5, 1998
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Wayne D. Inman, Steven Row King, Joseph L. Evans, Jian Luo
  • Patent number: 5691386
    Abstract: A novel hypoglycemically active triterpenoid compound isolated in purified, preferably substantially purified, form from Salacia spp., processes for obtaining the novel triterpenoid compound, compositions comprising the triterpenoid compound and methods for use a hypoglycemic agent, for example, in the treatment of diabetes, are described. In a preferred embodiment, the triterpenoid compound is obtained from Salacia prinoides. As an agent for the treatment of diabetes, the novel triterpenoid is useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.
    Type: Grant
    Filed: April 16, 1996
    Date of Patent: November 25, 1997
    Assignee: Shaman Pharmaceuticals, Inc.
    Inventors: Wayne D. Inman, Michael John Reed
  • Patent number: 4959370
    Abstract: This invention is directed to novel compounds of Formula (I): ##STR1## wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions formulated therewith. This invention is also directed to a method for treating helminthiasis and for inhibiting reverse transcriptase activity in an animal by the administration of compounds of Formula (I).
    Type: Grant
    Filed: March 29, 1989
    Date of Patent: September 25, 1990
    Inventors: Phillip Crews, Thomas R. Matthews, Wayne D. Inman